Form 4: Beam Therapeutics' Chief Medical Officer Sells Shares to Cover Tax Obligations and Under 10b5-1 Trading Plan
SEC Form 4 Filing
Amy Simon, Chief Medical Officer of Beam Therapeutics, sold shares of common stock on April 1st and 2nd, 2025, to cover tax obligations and under a pre-arranged 10b5-1 trading plan.
Summary
- Amy Simon, the Chief Medical Officer of Beam Therapeutics, filed a Form 4 disclosing changes in beneficial ownership.
- On April 1, 2025, she sold 9,566 shares of common stock at a weighted average price of $18.3506 per share to cover tax withholding obligations.
- These shares were related to the vesting of restricted stock units granted under the company's 2019 Equity Incentive Plan.
- The sales were executed automatically through a non-discretionary transaction as part of a Rule 10b5-1 trading plan adopted on May 19, 2023.
- On April 2, 2025, she sold 20,997 shares of common stock at a weighted average price of $17.7308 per share pursuant to a separate Rule 10b5-1 trading plan adopted on November 7, 2024.
- Following these transactions, Simon directly owns 65,742 shares of Beam Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock sales by an insider under pre-arranged trading plans and to cover tax obligations. There is no indication of positive or negative implications for the company's performance.
Industry Context
Sales by company insiders are a normal part of corporate activity. It is important to note that the sales were conducted under a pre-arranged 10b5-1 trading plan, which is a common practice to avoid accusations of insider trading. The plans are typically set up when the insider does not possess any material non-public information.
Stakeholder Impact
- The stock sales could have a minor, temporary impact on the stock price, but the pre-planned nature of the sales should mitigate any significant negative perception from shareholders.
Key Dates
| Date | Description |
|---|---|
| 2021-03-31 | Date of restricted stock unit grant under the Beam Therapeutics Inc. 2019 Equity Incentive Plan. |
| 2022-03-31 | Date of restricted stock unit grant under the Beam Therapeutics Inc. 2019 Equity Incentive Plan. |
| 2023-03-31 | Date of restricted stock unit grant under the Beam Therapeutics Inc. 2019 Equity Incentive Plan. |
| 2023-05-19 | Date the Reporting Person adopted a Rule 10b5-1 trading plan. |
| 2024-03-31 | Date of restricted stock unit grant under the Beam Therapeutics Inc. 2019 Equity Incentive Plan. |
| 2024-11-07 | Date the Reporting Person adopted a Rule 10b5-1 trading plan. |
| 2025-04-01 | Date of common stock sale to cover tax withholding obligations. |
| 2025-04-02 | Date of common stock sale pursuant to a Rule 10b5-1 trading plan. |
| 2025-04-03 | Date of Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Beam Therapeutics, Amy Simon, Chief Medical Officer, Stock Sale, Rule 10b5-1, Tax Withholding, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.